Bayer buys BlueRock Therapeutics, marks stance cell therapy space
Category: #health  By Mateen Dalal  Date: 2019-08-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Bayer buys BlueRock Therapeutics, marks stance cell therapy space
  • Versant Ventures’ portfolio company, Bluerock Therapeutics acquired by Bayer AG for approximately USD 1 billion.
  • This acquisition represents Versant’s robust progress in the region of Canada.

California headquartered Versant Ventures reportedly announced the acquisition of its cell therapy company BlueRock Therapeutics by Germany based Bayer AG which was valued at USD 1 billion. This represents an added important transaction by the Versant-formed companies.

As per credible sources, Versant considered the plan and commenced to build BlueRock in 2015 with opinion that stem cells had the potential to yield regenerative therapeutics based considering the fundamental advances achieved in cell differentiation, production and engineering.

Reportedly, the preliminary seed phase covered over a year allowing the required time to secure foundational technology from the recognized universities of Toronto and New York.

Speculation has it that in December 2016, BlueRock originated with USD 225 million in Series A round led by Versant and Bayer. Making use of this financing, the company extended its ranks with a commendable team including over more than 70 scientists at its R&D facility.

As per sources, Bayer has been claimed to acquire the shares in BlueRock for about USD 600 million, with about USD 240 million up front and up to USD 360 million preclinical and early clinical milestone payments.

Brad Bolzon, the Managing Director and chairman at Versant was reportedly quoted stating that the BlueRock acquisition strengthen the firms’ current approach to recognize the promising new discoveries happening in the field of science across the globe.

Jerel Davis, Managing Director, Versant and board director BlueRock was quoted stating that Versant has successfully established a Canadian presence to identify the unexploited sources of innovations in the emerging fields. The firm is looking forward for a global recognition with Bayer’s acquisition of BlueRock.

For the records, 1999 established Versant Ventures is a principal healthcare venture capital firm dedicated to helping excellent entrepreneurs build the next generation of great companies. The firm lays major emphasis on biotechnology companies that are currently discovering and evolving novel therapeutics.

Source credit: https://www.businesswire.com/news/home/20190808005234/en/Versant-Ventures-Announces-Acquisition-Cell-Therapy-Company

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...